A prognostic model for survival after salvage treatment with FLAG-Ida +/− gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A prognostic model for survival after salvage treatment with FLAG-Ida +/− gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia

Published:2016-04-26 Issue:5 Volume:174 Page:700-710
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bergua Juan M.¹,Montesinos Pau²,Martinez-Cuadrón David²,Fernández-Abellán Pascual³,Serrano Josefina⁴,Sayas María J.⁵,Prieto-Fernandez Julio¹,García Raimundo⁶,García-Huerta Ana J.⁷,Barrios Manuel⁸,Benavente Celina⁹,Pérez-Encinas Manuel¹⁰,Simiele Adriana¹¹,Rodríguez-Macias Gabriela¹²,Herrera-Puente Pilar¹³,Rodríguez-Veiga Rebeca²^ORCID,Martínez-Sánchez María P.¹⁴,Amador-Barciela María L.¹⁵,Riaza-Grau Rosalía¹⁶,Sanz Miguel A.²,

Affiliation:

1. Department of Haematology; Hospital San Pedro de Alcántara; Cáceres Spain

2. Department of Haematology; University Hospital La Fe; Valencia Spain

3. Department of Haematology; General Hospital Alicante; Alicante Spain

4. Department of Haematology; Hospital Reina Sofia; Córdoba Spain

5. Department of Haematology; Hospital Doctor Peset; Valencia Spain

6. Department of Haematology; General Hospital Castellón; Castellón Spain

7. Department of Haematology; Central Hospital of Asturias; Oviedo Spain

8. Department of Haematology; Hospital Carlos Haya; Málaga Spain

9. Department of Haematology; Clinic Hospital; Madrid Spain

10. Department of Haematology; Clinic Hospital; Santiago de Compostela Spain

11. Department of Haematology; Hospital Povisa; Vigo Spain

12. Department of Haematology; Hospital Gregorio Marañon; Madrid Spain

13. Department of Haematology; Hospital Ramón y Cajal; Madrid Spain

14. Department of Haematology; Hospital 12 de Octubre; Madrid Spain

15. Department of Haematology; Hospital Montecelo; Pontevedra Spain

16. Department of Haematology; Hospital Severo Ochoa; Leganés Spain

Funder

Junta de Extremadura

Fundación Española de Hematología (FEHH)

Red Temática de Investigación Cooperativa en Cancer

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14107/fullpdf

Reference32 articles.

1. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia;Amadori;Journal of Clinical Oncology,1991

2. Prognostic index for adult patients with acute myeloid leukemia in first relapse;Breems;Journal of Clinical Oncology,2005

3. Revised Recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia;Cheson;Journal of Clinical Oncology,2003

4. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukemia;Chevallier;Journal of Clinical Oncology,2008

5. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study;Chevallier;Leukemia,2011

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Study from a Single-Center;Current Medical Science;2023-12

2. Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG);Journal of Geriatric Oncology;2023-09

3. Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia;Haematologica;2023-07-20

4. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia;Cancers;2022-06-06

5. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan;Bone Marrow Transplantation;2022-05-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3